Year :
2024
| Month :
April
| Volume :
18
| Issue :
4
| Page :
UC12 - UC16
Impact of Albumin Therapy in Critically Ill COVID-19 Patients: A Retrospective Cohort Study
Bonchanpalli Mohan Kumar, Mustahsin Malik, Rajesh Kumar
1. Junior Resident, Department of Critical Care Unit and Anaesthesiology, Era’s Lucknow Medical College and Hospital, Lucknow, Uttar Pradesh, India.
2. Professor, Department of Critical Care Unit and Anaesthesiology, Era’s Lucknow Medical College and Hospital, Lucknow, Uttar Pradesh, India.
3. Assistant Professor, Department of Critical Care Unit and Anaesthesiology, Era’s Lucknow Medical College and Hospital, Lucknow, Uttar Pradesh, India.
Correspondence Address :
Dr. Rajesh Kumar,
Department of Anaesthesiology, Era’s Lucknow Medical University and Hospital, Lucknow-226003, Uttar Pradesh, India.
E-mail: docraj198810@gmail.com
Abstract
Introduction: Coronavirus Disease 2019 (COVID-19) is an infectious disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Due to the limited understanding of this disease, research has quickly extended towards identifying biomarkers to predict its prognosis and progression.
Aim: To explore the impact of albumin infusion on critically ill COVID-19 patients.
Materials and Methods: In this retrospective cohort study, a total of 150 severe COVID-19 patients aged 18 to 65 years were enrolled. These patients were categorised into the no albumin infusion group (n=61), consisting of those who did not undergo albumin transfusion during their treatment, and the albumin infusion group (n=89), comprising patients who received albumin transfusion as part of their treatment protocol. Assessments of hospitalisation included the Sequential Organ Failure Assessment (SOFA), and Acute Physiology and Chronic Health Evaluation (APACHE-II) scores obtained at baseline and day 5. Unpaired t-tests, Chi-square tests, and paired t-tests were used for analysis.
Results: The mean values of Haemoglobin (Hb), eosinophils, Random Blood Sugar (RBS), Mean Corpuscular Volume (MCV), total protein, serum urea, serum bilirubin, Prothrombin Time (PT), International Normalised Ratio (INR), Interleukin 6 (IL-6), Erythrocyte Sedimentation Rate (ESR), C-Reactive Protein (CRP), and D-dimer exhibited significant differences between the two groups. The average duration of vasopressor usage and Intensive Care Unit (ICU) stay were significantly reduced in the albumin infusion group (3.50±1.55 days and 8.70±4.20 days, respectively) compared to no albumin infusion group (4.33±1.05 days and 12.80±3.43 days, respectively). The albumin infusion group also displayed a lower incidence of Renal Replacement Therapy (RRT) and poorer ICU outcomes.
Conclusion: The intravenous administration of albumin did not exhibit a significant impact on mortality. However, albumin transfusion in patients with severe COVID-19 who initially had albumin levels <3 g/dL demonstrated a notable reduction in the requirement for vasopressors, RRT, and the length of ICU stay.
Keywords
Albumin infusion, Hypoalbuminemia, Intensive care unit stay, Mortality, Vasopressor
DOI and Others
DOI: 10.7860/JCDR/2024/68774.19236
Date of Submission: Nov 25, 2023
Date of Peer Review: Dec 11, 2023
Date of Acceptance: Feb 10, 2024
Date of Publishing: Apr 01, 2024
AUTHOR DECLARATION:
• Financial or Other Competing Interests: None
• Was Ethics Committee Approval obtained for this study? Yes
• Was informed consent obtained from the subjects involved in the study? No
• For any images presented appropriate consent has been obtained from the subjects. No
PLAGIARISM CHECKING METHODS:
• Plagiarism X-checker: Nov 25, 2023
• Manual Googling: Dec 14, 2023
• iThenticate Software: Feb 08, 2024 (9%)
ETYMOLOGY: Author Origin
EMENDATIONS: 10
|